251 related articles for article (PubMed ID: 26322830)
1. Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.
Zheng Y; Ishiguro H; Ide H; Inoue S; Kashiwagi E; Kawahara T; Jalalizadeh M; Reis LO; Miyamoto H
Mol Endocrinol; 2015 Oct; 29(10):1486-97. PubMed ID: 26322830
[TBL] [Abstract][Full Text] [Related]
2. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.
Lesovaya EA; Yemelyanov AY; Kirsanov KI; Yakubovskaya MG; Budunova IV
Biochemistry (Mosc); 2011 Nov; 76(11):1242-52. PubMed ID: 22117551
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
5. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
[TBL] [Abstract][Full Text] [Related]
6. Compound A inhibits urothelial tumorigenesis via both the androgen receptor and glucocorticoid receptor signaling pathways.
Ide H; Inoue S; Mizushima T; Jiang G; Nagata Y; Goto T; Kashiwagi E; Miyamoto H
Am J Transl Res; 2020; 12(5):1779-1788. PubMed ID: 32509176
[TBL] [Abstract][Full Text] [Related]
7. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
[TBL] [Abstract][Full Text] [Related]
8. Role of glucocorticoid signaling in urothelial tumorigenesis: Inhibition by prednisone presumably through inducing glucocorticoid receptor transrepression.
Ide H; Inoue S; Mizushima T; Kashiwagi E; Zheng Y; Miyamoto H
Mol Carcinog; 2019 Dec; 58(12):2297-2305. PubMed ID: 31535408
[TBL] [Abstract][Full Text] [Related]
9. The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A.
Kowalczyk P; Kowalczyk MC; Junco JJ; Tolstykh O; Kinjo T; Truong H; Walaszek Z; Hanausek M; Slaga TJ
Mol Carcinog; 2013 Jun; 52(6):488-96. PubMed ID: 22351517
[TBL] [Abstract][Full Text] [Related]
10. GR-independent down-modulation on GM-CSF bone marrow-derived dendritic cells by the selective glucocorticoid receptor modulator Compound A.
Barcala Tabarrozzi AE; Andreone L; Deckers J; Castro CN; Gimeno ML; Ariolfo L; Berguer PM; Antunica-Noguerol M; Liberman AC; Vettorazzi S; Tuckermann JP; De Bosscher K; Perone MJ
Sci Rep; 2016 Nov; 6():36646. PubMed ID: 27857212
[TBL] [Abstract][Full Text] [Related]
11. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals.
Zheng Y; Izumi K; Li Y; Ishiguro H; Miyamoto H
Mol Cancer Ther; 2012 Dec; 11(12):2621-32. PubMed ID: 23033490
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids and the non-steroidal selective glucocorticoid receptor modulator, compound A, differentially affect colon cancer-derived myofibroblasts.
Drebert Z; Bracke M; Beck IM
J Steroid Biochem Mol Biol; 2015 May; 149():92-105. PubMed ID: 25666906
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis.
Wüst S; Tischner D; John M; Tuckermann JP; Menzfeld C; Hanisch UK; van den Brandt J; Lühder F; Reichardt HM
PLoS One; 2009 Dec; 4(12):e8202. PubMed ID: 19997594
[TBL] [Abstract][Full Text] [Related]
14. Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1.
De Bosscher K; Beck IM; Dejager L; Bougarne N; Gaigneaux A; Chateauvieux S; Ratman D; Bracke M; Tavernier J; Vanden Berghe W; Libert C; Diederich M; Haegeman G
Cell Mol Life Sci; 2014 Jan; 71(1):143-63. PubMed ID: 23784308
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a.
Robertson S; Allie-Reid F; Vanden Berghe W; Visser K; Binder A; Africander D; Vismer M; De Bosscher K; Hapgood J; Haegeman G; Louw A
J Biol Chem; 2010 Mar; 285(11):8061-75. PubMed ID: 20037160
[TBL] [Abstract][Full Text] [Related]
16. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.
Izumi K; Zheng Y; Li Y; Zaengle J; Miyamoto H
Int J Oncol; 2012 Nov; 41(5):1587-92. PubMed ID: 22922989
[TBL] [Abstract][Full Text] [Related]
19. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Lesovaya E; Yemelyanov A; Kirsanov K; Popa A; Belitsky G; Yakubovskaya M; Gordon LI; Rosen ST; Budunova I
Cell Cycle; 2013 Jan; 12(1):133-44. PubMed ID: 23255118
[TBL] [Abstract][Full Text] [Related]
20. Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies.
Clarisse D; Van Wesemael K; Tavernier J; Offner F; Beck IM; De Bosscher K
PLoS One; 2018; 13(5):e0197000. PubMed ID: 29738549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
